Novack Gary D
PharmaLogic Development, Inc, San Rafael, California; and Departments of Pharmacology and Ophthalmology, University of California, Davis, Davis, California.
Am J Ophthalmol. 2016 Jul;167:48-51. doi: 10.1016/j.ajo.2016.04.010. Epub 2016 Apr 27.
To evaluate the cost paid by patients in the United States for their branded, prescription medication, and the factors that determine the cost.
Evaluation of publicly available information on the U.S. pharmaceutical distribution system.
Review of public information and interpretation based on the author's experience.
The price paid for branded, prescription medication by an insured patient is set by the patient's insurance company-not the manufacturer, distributor, or pharmacy-and is typically a co-pay, which is a fraction of the wholesale acquisition cost (WAC). On the other hand, for an uninsured patient, the patient cost is higher than the WAC and may vary dramatically, depending on the pharmacy. Furthermore, lowering of the WAC by the manufacturer (eg, a new product in the same class) may not lower the patient payment, as that cost is set by the insurer and may depend on rebates from the manufacturer to the distributor and to the insurer. The proportion of patients in the United States covered by insurance is growing.
In the same way that the mean (or median) may not accurately describe a bimodal population, the WAC does not accurately describe the cost of branded, prescription medication to patients. To reduce medication costs to patients, recommendations are as follows: (1) selection of insurance plans whose formularies cover their medications in a low tier (eg, "Preferred"), (2) for patients without insurance, price compare at multiple pharmacies; (3) use manufacturer-supplied coupons to reduce out-of-pocket costs, and (4) consider therapeutics-optimal use of medications often executable with little or no cost to the patient.
评估美国患者购买品牌处方药的花费以及决定花费的因素。
对美国药品分销系统公开信息的评估。
基于作者经验对公开信息进行审查和解读。
参保患者购买品牌处方药的价格由患者的保险公司设定,而非制造商、经销商或药房,通常是一种自付费用,即批发采购成本(WAC)的一部分。另一方面,对于未参保患者,患者费用高于WAC,且可能因药房不同而有很大差异。此外,制造商降低WAC(例如同一类别的新产品)可能不会降低患者支付的费用,因为该费用由保险公司设定,可能取决于制造商给经销商和保险公司的回扣。美国参保患者的比例正在增加。
就像均值(或中位数)可能无法准确描述双峰分布人群一样,WAC也无法准确描述品牌处方药对患者的成本。为降低患者的用药成本,建议如下:(1)选择其处方集将其药物列为低级别(例如“首选”)的保险计划;(2)对于未参保患者,在多家药房比较价格;(3)使用制造商提供的优惠券以降低自付费用;(4)考虑治疗方法——通常患者只需很少费用或无需费用就能实现药物的最佳使用。